AQST - Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities | Benzinga
- Sherry Korczynski joins the leadership team as Senior Vice President, Sales and Marketing
- Dr. Stephen Wargacki promoted to Chief Science Officer
- Cassie Jung named Chief Operating Officer
WARREN, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm™ (epinephrine) Sublingual Film, the Company's epinephrine prodrug product candidate that has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the U.S. Food and Drug Administration (FDA). Sherry Korczynski joined the Aquestive leadership team as Senior Vice President, Sales and Marketing. Cassie Jung was promoted to Chief Operating Officer, and Stephen Wargacki, Ph.D., was named Chief Science Officer.
Ms. Korczynski brings over 20 years of progressive experience leading product launches and commercialization efforts for biopharmaceutical companies and has prior expertise in the allergy field. Ms. Korczynski previously served as Vice President, EpiPen® Marketing and Public Relations at Mylan (now Viatris Inc.), where she directed a multi-faceted commercial strategy for a billion-dollar allergy product. In addition, she previously served as Vice President, Marketing, Public Relations and Advocacy at ANI Pharmaceuticals, Inc., where she developed the launch plan for a rare disease product. Ms. Korczynski also served as Senior Vice President, Marketing & Public Relations at Eagle Pharmaceuticals, Inc., where she led the marketing and public relations campaigns for multiple brands and product launches.
Dr. Stephen Wargacki joined Aquestive in 2015 and has held positions of increasing responsibility since joining the Company. Most recently, Dr. Wargacki was Aquestive's Senior Vice President of Research and Development. In his 14 years in the pharmaceutical industry, he has been focused on alternative drug delivery, including transdermal, sublingual, and buccal delivery systems, as well as on several medical devices. Dr. Wargacki was instrumental in the identification and development of the Company's epinephrine prodrug platform.
Ms. Jung joined Aquestive in 2004 and has held leadership positions across various areas of the business, including Quality Assurance, Alliance Management, Clinical Operations, and Portfolio Management. Ms. Jung was instrumental in the execution of Aquestive's internal CNS development pipeline and was appointed Senior Vice President, Operations in 2019, with responsibility for all facets of the Company's manufacturing operations.
"I am pleased to welcome Sherry to the Aquestive team," said Dan Barber, President and Chief Executive Officer of Aquestive. "Sherry brings two decades of experience leading commercialization efforts and launching pharmaceutical products to her leadership role at Aquestive. Her experience in the allergy space, specifically with EpiPen, ...